Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4491

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Lurasidone HCI tablet in a 40mg dose with 30 tablets per quantity. The medication is round, white in color with an imprint "L;2". The manufacturer is Camber Pharma, Inc. and it was repackaged by RemedyRepack Inc. The usual dosage instructions can be found in the insert. The medication should be kept away from children and stored at a temperature between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F).*

FDA Label Image

Lurasidonehclfig1 (Lurasidonehclfig1)

This text provides a list of interacting drugs categorized based on their effects on CYP3A4 enzymes, with examples of strong inhibitors like Ketoconazole, moderate inhibitors like Diltiazem, and a strong inducer like Rifampin. It also mentions dosages such as 400 mg/day for Ketoconazole and 240 mg/day for Diltiazem. Additionally, there is a mention of the drug Lithium at a dosage of 600 mg BID. The text refers to PK, fold change, 90% CI, and change relative to lurasidone alone for these interacting drugs.*

FDA Label Image

Lurasidonehclfig2 (Lurasidonehclfig2)

This text provides information on the drug interactions and pharmacokinetics of various substances such as digoxin, midazolam, oral contraceptives containing ethinyl estradiol and norelgestromin, and lithium. It also mentions fold change and 90% confidence interval in relation to interactive drugs.*

FDA Label Image

Lurasidonehclfig3 (Lurasidonehclfig3)

This text provides information regarding PK fold change and 90% C1 related to renal and hepatic impairment. It also discusses population descriptions including gender and race, specifically focusing on females and Asian individuals in comparison to Caucasians. The text suggests variations in Cmax and AUC levels based on different levels of impairment and demographic factors.*

FDA Label Image

Lurasidonehclstructure (Lurasidonehclstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.